In this on-demand recording of part 1 of this webinar series, you'll discover why you need to consider AI and ML approaches to risk management and learn from the case study of a pharma organization that used AI/ML-based risk models to determine exactly when to restart its clinical trials during the Coronavirus pandemic.
Forward-Looking Risk: Enabling the Anti-Fragile Organization in the New Normal
Posted May 7, 2020 | Leadership |
About The Author
Tom Teixeira is a Partner with Arthur D. Little (ADL), based in London. He has more than 20 years’ risk management experience, both in senior consulting and operational roles. Mr. Teixeira’s key areas of expertise include risk-based strategic planning and forecasting; risk analysis and quantification; total cost of risk reduction strategies, including insurance and captive management; and governance, risk, and compliance technology platforms. He… Read More
Craig Wylie is a Managing Partner at Arthur D. Little (ADL), based in Boston; and a member of ADL's global Healthcare & Life Sciences practice. His expertise is in the regulated functions of the life sciences industry, in particular, post-merger integration, R&D strategy and operations, inspection readiness, and findings remediation. Mr. Wylie's background is in R&D and quality operations, and he strongly believes that effective… Read More
Don’t have a login?
Make one! It’s free and gives you access to all Cutter research.